Since September 2007, Dr Parkinson has served as president and CEO of Nodality, a South San Francisco, California-based biotechnology company. Dr Parkinson has received his MD degree from the University of Toronto Faculty of Medicine and hematology/oncology training at McGill University and New England Medical Center.
Upon completion of the spin-off transaction, Facet Biotech will focus on advancing the company’s current pipeline of four clinical-stage products, and leveraging the company’s R&D capabilities to identify and develop new drugs.
Brad Goodwin, chairperson of board of directors at PDL, said: “We are pleased to have a scientist and clinician of David’s caliber join Facet’s board of directors. David’s experience in oncology research and drug development will be invaluable as we focus our efforts to establish Facet as an exciting and promising biotech company.”